Dogwood Therapeutics reported a net loss of $11.5 million for the second quarter ended June 30, 2026, or $0.34 per share, driven by a $9.2 million non-cash IPR&D impairment charge and increased R&D expenses of $3.2 million. The company announced a worldwide development and commercialization partnership for legacy antiviral assets with potential value up to $100 million to Dogwood and its CVR holders. Halneuron Phase 2b trial enrollment reached 217 patients, with top-line results expected in fall 2026, while SP16 received FDA IND approval for a fully NCI-funded Phase 1b study beginning in the second half of 2026. Cash on hand stands at $9.6 million, providing runway through the fourth quarter 2026. Dogwood Therapeutics is a biopharmaceutical company developing non-opioid medicines to treat pain and neuropathic disorders.

At its annual meeting on June 16, 2026, Dogwood Therapeutics, Inc. stockholders approved an amendment to the Certificate of Incorporation to increase the number of authorized shares of common and preferred stock. The meeting also resulted in the following voting results: election of seven directors, ratification of Forvis Mazars, LLP as independent auditor, and approval of advisory votes on executive compensation frequency and compensation. Dogwood Therapeutics, Inc. is a biotechnology company that develops therapeutic solutions for various medical conditions.